Phase II study of Efficacy and Safety of SJE-2079 in the Treatment for Diabetic Macular Edema
Phase of Trial: Phase II
Latest Information Update: 29 Jul 2016
Price : $35 *
At a glance
- Drugs Difluprednate (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Sponsors Senju Pharmaceutical
- 28 Jul 2016 Status changed from active, no longer recruiting to completed.
- 26 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by University Hospital Medical Information Network - Japan record.
- 02 Oct 2013 New trial record